The same exoskeleton that helps a stroke survivor walk is being adapted for factory workers and soldiers. Three companies—Ekso Bionics, Wearable Robotics, and Wandercraft—are building platforms that cross the medical-industrial divide.
Space-based quantum key distribution is moving from labs to market. SEALSQ is building a 100-satellite constellation. SpeQtral launched its CubeSat. The gap between ambition and operational reality is still wide.
SYOS unveils the SU10 underwater drone for minehunting, maritime surveillance, and subsea cable protection. How a four-year-old Kiwi-British startup became a multi-domain defence supplier.
$455M market by 2034. Varda signed the first commercial pharma deal in orbit. BioOrbit flew crystals on the ISS. Inside the emerging orbital drug manufacturing industry.
Five-year data from the KEYNOTE-942 trial shows Moderna and Merck's personalized mRNA cancer vaccine (intismeran autogene) cut melanoma recurrence by 49% when combined with Keytruda — and the effect held from year three to year five.
Cambium's ApexShield 1000 resin cuts hypersonic thermal protection fabrication time by 80%. Altrove, CuspAI, and a new generation of AI materials startups are compressing discovery timelines from decades to months. But the gap between lab and launchpad remains wide.
Three BCI companies raised over $500M in 12 months. Synchron, Neuralink, and Paradromics are crossing from clinical trials into commercial deployment — and defence teleoperation is the next frontier for neural control of drones and robotic systems.
Eighty percent of the human proteome is classified as undruggable. The surfaces are smooth. The binding pockets are missing. Conventional small molecules slide off them like water off wax. In the first half of 2026 alone, more than €8 million in seed and early-stage capital flowed into a single
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
